Biogenvs.BioMarin Pharmaceutical
BIIB vs BMRN · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Biogen is about 2.6× larger than BioMarin Pharmaceutical by market cap; Biogen trades at the lower P/E (21.3 vs 42.6); year to date, Biogen leads (+13.2% vs −0.5%).
Side by side
| BIIB | BMRN | |
|---|---|---|
| Market cap | $29.3B | $11.4B |
| Price | $199.15 | $59.12 |
| Today | +0.1% | −1.4% |
| Return YTD | +13.2% | −0.5% |
| Return 1Y | +47.2% | +0.5% |
| P/E | 21.3 | 42.6 |
| P/S | 2.9 | 3.5 |
| P/B | 1.6 | 1.8 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
BiogenBIIB
American biotech company focused on neurological diseases — including Alzheimer's (Leqembi, with Eisai) and MS.
Full BIIB profile →BioMarin PharmaceuticalBMRN
Biopharma specialized in enzyme and gene therapies for rare genetic diseases.
Full BMRN profile →More comparisons in Biotech & innovation
See where BIIB and BMRN sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →